Google, Amazon, Facebook and Apple Propel the Life Sciences Industry with Strategic Partnerships

Health, Technology

Frost & Sullivan’s recent analysis,  Global Life Sciences Industry Outlook, 2018, finds that healthcare digitization and consumerization, the explosion of patient data, and the emergence of value-based reimbursement models, are propelling the life sciences industry towards the $1.5 trillion milestone. The convergence of biopharmaceuticals, drug delivery devices, and companion diagnostics —enabled by digital connectivity— is driving regulatory and commercial changes in many exciting ways for the industry.

“The scope for synergies among disciplines is attracting big tech companies such as GoogleAmazonFacebookApple (GAFA) to the life sciences industry,” said Unmesh Lal, Program Manager, Transformational Health. “The adoption of artificial intelligence (AI) and cloud-based solutions for drug discovery and clinical trial workflow is improving the overall efficiency of production. Additionally, pathology and research laboratories are increasingly adopting health analytics solutions to track the test utilization and efficiently tackle reimbursement issues.”

For further information on this analysis, please visit: http://frost.ly/2ii

In 2018, innovations and new business models spun around data monetization as a result of value-based medicine; a connected ecosystem will be the most talked about areas. Incorporation of advanced technologies will drive the delivery of precision healthcare, raising the following growth opportunities:

  • AI and cloud deployment in pharma research and development (R&D): Drug discovery and clinical development IT solutions spending to exceed $10 billion in 2018;
  • Convergence of molecular diagnostics and big data analytics:Disruptive startups with oncology diagnostics portfolio will see high rewards from their investments;
  • Smart genomics: Research labs jump-start spending on cloud, NGS and big data analytics solutions;
  • Biopharma partnerships with contract development and manufacturing organizations (CDMO) and contract research organizations (CRO): Outsourcing of bio-analytical and current good manufacturing practice (cGMP) services is expected to reach $8.5 billion in 2018;
  • Liquid biopsy and companion diagnostics: Roughly $500 millionin venture capital funding is expected to flood the liquid biopsy space as companion diagnostic-based liquid biopsy tests gain approval from the regulatory authority; and
  • Biotech expansion into CAR-T and gene therapies: Favorable tax reforms and competition for new assets could lead to higher valuations and product deal amounts.

“While the cell and gene therapy segments have shown potential, pharmaceutical and biotechnology companies continue to invest in the promising segments of oncology, cardiovascular, diabetes, and immunology. These segments not only have high unmet needs but also have high acceptability across regions,” noted Lal. “Overall personalization, decentralization, collaboration, and prevention are amplifying precision health, thereby shaping the future business models and the workforce of life sciences companies.”

Global Life Sciences Industry Outlook, 2018 is part of Frost & Sullivan’s global Life Sciences Growth Partnership Service program.

California Cryobank And Cord Blood Registry To Be Combined By GI Partners To Create A Leading Life Sciences Platform

Business, Health

California Cryobank, the world’s leading donor sperm and donor egg bank, announced today that it has signed a definitive agreement for GI Partners, a private equity investment firm, to acquire the company from leading healthcare investors Longitude Capital and NovaQuest Capital.

In a separate transaction announced today, GI Partners has also entered into a definitive agreement with AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) to acquire Cord Blood Registry (CBR), the world’s largest stem cell collection and storage company. Following the close of both transactions, California Cryobank and CBR will join together in a newly combined entity that will operate under the California Cryobank Life Sciences platform, bringing together best-in-class organizations to provide enhanced domestic and international expansion opportunities in both the donor reproductive tissue and newborn stem cell industries.

Dave Kreter, Managing Director at GI Partners said, “We have been following the growing and dynamic reproductive and stem cell space for several years and were attracted to these two companies by their robust customer and market characteristics. Their combination represents a unique opportunity to create a new platform better positioned to further expand their industry leading capabilities. We are excited to collaborate with management to extend the combined company’s capabilities internationally and make critical investments to support its next phase of growth.”

Recognized as the world’s premier donor sperm and egg bank, California Cryobank has been an industry leader and innovator since 1977. Together, the donor sperm and donor egg banks have helped over 75,000 families.

Richard Jennings, California Cryobank CEO, commented that: “The Life Sciences platform created by the combination of our two companies will allow us to utilize our collective strengths more effectively, and achieve our vision of helping to grow and protect healthy families around the world. CBR is the most recognized cord blood brand among expectant parents and we are excited to expand CBR’s presence in the newborn stem cell market even further given California Cryobank’s global footprint. Cord blood and cord tissue offer a once-in-a-lifetime opportunity to protect families against 80 diseases, and give clients the biologic resource to utilize clinical therapies within regenerative medicine.”

“We are bringing together the leaders in two complementary, family-focused industries,” explained California Cryobank COO Pamela Richardson. “Both organizations set the standard for clinical excellence, customer experience, physician relations, and overall quality. The combination will provide enhanced value to our clients. CBR is a perfect fit with California Cryobank’s mission of providing the highest quality reproductive and stem cell services, guided by dedicated customer focus, unmatched scientific excellence, and innovative leadership.”

Dr. Greg Grunberg, Managing Director at Longitude Capital said, “Over the course of the last four decades, California Cryobank has helped countless families achieve their most fundamental of aspirations. We are thrilled to provide our continued support to our world class management team, which upholds the highest moral, ethical, and scientific standards, as California Cryobank expands its vital services and advances the fields of reproductive and regenerative medicine.”

William O. Robb, Founding Partner of NovaQuest Capital Management added, “The combination of CCB and CBR demonstrates this management team’s success in positioning California Cryobank Life Sciences as the leading reproductive services platform in the world. The immediate and longer-term synergies between CCB and CBR in donor sperm, donor egg, and stem cell services will create a critical partner to the families, physicians, and other key stakeholders in the growing reproductive sciences field.”